Replies to post #2056 on Biostax Corp (BTAX)

[RFB]

Irregardless of the applications, it does not take away from the fact IMUN management can not turn revenue/profit quick enough and for the short-medium term this will continue to experience depreciation and likely dilution to fund future operations. The financing is borderline toxic and not favorable at all to IMUN or any current shareholder, not that I expected anything different from OTC land. Either way, the 8K released the toxic nature of the deal.
Yet another OTC penny that looks promising, but yet will under-deliver due to corrupt financing. The PPS is speaking for itself, with the bid and ask collapsing slowly (due to anemic volume) since the 8K and latest PR and will continue to depreciate for the foreseeable future. My advice...BUYER BEWARE!!!